Intravenous immune globulin usage for neurological and neuromuscular disorders: An academic centre, 4 years experience

Neurological Sciences

Volumn 30, Issue 3, 2009, Pages 213-218

  Sarti, Lisa ^a   Falai, Tiziana ^a   Pinto, Francesco ^a   Tendi, Enrico ^a   Matà, Sabrina ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Dysimmune neuropathies; Intravenous immunoglobulin; IVIg shortage

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG INDICATION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MUSCLE DISEASE; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEUROMUSCULAR JUNCTION DISORDER; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; RECOMMENDED DRUG DOSE; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NEUROMUSCULAR DISEASES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 67349124173     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-009-0043-9     Document Type: Article

References (25)

1. Jolles S, Sewell WA, Misbah SA (2005) Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142:1-11
2. Lemieux R, Bazin R, Néron S (2005) Therapeutic intravenous immunoglobulins. Mol Immunol 42:839-848
3. Lin MW, Kirkpatrick PE, Riminton DS (2007) How intravenous immunoglobulin is used in clinical practice: Audits of two Sydney teaching hospitals. Intern Med J 37:308-314
4. Hughes RA, Raphael JC, Swan AV, van Doorn PA (2004) Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. CD002063
5. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A, Inflammatory Neuropathy Cause, Treatment (INCAT) Group (2001) Randomized controlled trial of intravenous mmunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195-201
6. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE (2000) Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study. Neurology 55:1256-1262
7. Gray O, McDonnell GV, Forbes RB (2003) Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst Rev. CD002936
8. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993-2000
9. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C (1997) Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 41:789-796
10. Wiles CM, Brown P, Chapel H, Guerrini R, Hughes RA, Martin TD, McCrone P, Newsom-Davis J, Palace J, Rees JH, Rose MR, Scolding N, Webster AD (2002) Intravenous immunoglobulin in neurological disease: A specialist review. J Neurol Neurosurg Psychiatry 72:440-448
11. Linker RA, Gold R (2008) Use of intravenous immunoglobulin and plasma exchange in neurological disease. Curr Opin Neurol 21:358-365
12. Feasby T, Banwell B, Benstead T, Bril V, Brouwers M, Freedman M, Hahn A, Hume H, Freedman J, Pi D, Wadsworth L (2007) Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 21(2 Suppl 1):S57-S107
13. Nimmerjahn F, Ravetch JV (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26:513-533
14. Rodriguez M, Miller DJ, Lennon VA (1996) Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 46:538-545
15. Gabriel CM, Gregson NA, Redford EJ, Davies M, Smith KJ, Hughes RA (1997) Human immunoglobulin ameliorates rat experimental autoimmune neuritis. Brain 120:1533-1540
16. Chan H, Heddle N (2004) Analysis of dosing variability of IVIG in community and teaching hospitals [abstract]. Blood 104:2726
17. Gajewski LK, Bailey EM, Brown PD, Chandrasekar PH (1994) Immune globulin use at a multihospital medical center. Am J Hosp Pharm 51:801-805
18. Lee YC, Woodfield DG, Douglas R (1998) Clinical usage of intravenous immunoglobulins in Auckland. N Z Med J 111:48-50
19. Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA (2000) A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centres. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacother 34:295-299
20. Farrugia A, Poulis P (2001) Intravenous immunoglobulin: Regulatory perspectives on use and supply. Transfus Med 11:63-74
21. Future Present Users of IVIG: A Canadian Multidisciplinary Consensus Building Initiative (1997) Can J Allergy Clin Immunol 2:176-208
22. Tumani H (2006) Rare indications of IVIG therapy in neurological diseases based on case reports and small studies. J Neurol 253(Suppl 5):V66-V69
23. Pendergrast JM, Sher GD, Callum JL (2005) Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995-2000. Vox Sang 89:150-160
24. Finsterer J (2005) Treatment of immune-mediated, dysimmune neuropathies. Acta Neurol Scand 112:115-125
25. Dalakas MC (2002) Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59:S13-S21